EMCURE - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.8
| Stock Code | EMCURE | Market Cap | 33,704 Cr. | Current Price | 1,776 ₹ | High / Low | 1,830 ₹ |
| Stock P/E | 44.8 | Book Value | 196 ₹ | Dividend Yield | 0.17 % | ROCE | 23.7 % |
| ROE | 22.3 % | Face Value | 10.0 ₹ | DMA 50 | 1,679 ₹ | DMA 200 | 1,524 ₹ |
| Chg in FII Hold | -0.24 % | Chg in DII Hold | 0.00 % | PAT Qtr | 228 Cr. | PAT Prev Qtr | 282 Cr. |
| RSI | 58.7 | MACD | 18.2 | Volume | 89,847 | Avg Vol 1Wk | 2,84,264 |
| Low price | 1,229 ₹ | High price | 1,830 ₹ | PEG Ratio | 0.68 | Debt to equity | 0.43 |
| 52w Index | 91.0 % | Qtr Profit Var | 63.4 % | EPS | 38.7 ₹ | Industry PE | 32.5 |
📊 EMCURE shows strong fundamentals and decent technicals for swing trading. ROCE (23.7%) and ROE (22.3%) are healthy, while EPS of 38.7 ₹ supports profitability. Debt-to-equity is moderate at 0.43, but manageable. The P/E ratio (44.8) is higher than industry average (32.5), suggesting slight overvaluation, though PEG ratio (0.68) indicates growth potential. RSI at 58.7 is neutral, and MACD at 18.2 signals bullish momentum. The stock trades above both 50 DMA (1,679 ₹) and 200 DMA (1,524 ₹), confirming an uptrend. However, PAT declined (228 Cr vs 282 Cr), and FII holdings reduced slightly (-0.24%).
💡 Optimal Entry Price: Around 1,670–1,700 ₹ (near 50 DMA support).
📈 Exit Strategy: If already holding, consider exiting near 1,820–1,830 ₹ (recent high resistance) or trail stop-loss to lock gains if momentum continues.
Positive
- 📌 [Strong ROCE](ca://s?q=EMCURE_ROCE): ROCE of 23.7% reflects efficient capital use.
- 📌 [Healthy ROE](ca://s?q=EMCURE_ROE): ROE of 22.3% indicates solid shareholder returns.
- 📌 [EPS Strength](ca://s?q=EMCURE_EPS): EPS of 38.7 ₹ highlights profitability.
- 📌 [Bullish Technicals](ca://s?q=EMCURE_MACD_RSI): MACD positive and RSI neutral support upward momentum.
Limitation
- ⚠️ [High Valuation](ca://s?q=EMCURE_high_PE): P/E ratio of 44.8 is above industry average (32.5).
- ⚠️ [Profit Decline](ca://s?q=EMCURE_quarterly_profit): PAT fell from 282 Cr to 228 Cr.
- ⚠️ [FII Reduction](ca://s?q=EMCURE_FII_holdings): Foreign institutional investors reduced holdings by 0.24%.
Company Negative News
- ❌ [Quarterly Profit Drop](ca://s?q=EMCURE_profit_drop): PAT decreased compared to previous quarter.
- ❌ [FII Exit](ca://s?q=EMCURE_FII_exit): Foreign investors reduced holdings slightly.
Company Positive News
- ✅ [Strong EPS](ca://s?q=EMCURE_EPS): EPS of 38.7 ₹ supports valuation.
- ✅ [Dividend Yield](ca://s?q=EMCURE_dividend_yield): Yield of 0.17% provides shareholder returns.
- ✅ [Market Cap Strength](ca://s?q=EMCURE_market_cap): Market cap of 33,704 Cr indicates industry relevance.
Industry
- 🏭 [Industry PE](ca://s?q=Pharma_industry_PE): Industry average P/E is 32.5, lower than EMCURE’s valuation.
- 🏭 [Sector Outlook](ca://s?q=Pharma_sector_outlook): Pharma sector benefits from steady demand and global healthcare expansion.
Conclusion
📈 EMCURE is a fairly strong candidate for swing trading. Fundamentals are solid, growth potential is evident, and technicals show bullish signals. Entry near 1,670–1,700 ₹ offers a favorable setup, with exit targets around 1,820–1,830 ₹. Risks include profit decline and slight FII reduction, but overall strength and industry positioning make it suitable for short-term gains.